[Bisphosphonates-related osteonecrosis of the jaw: A case report]
- PMID: 40219574
- PMCID: PMC11992463
- DOI: 10.19723/j.issn.1671-167X.2025.02.026
[Bisphosphonates-related osteonecrosis of the jaw: A case report]
Abstract
Osteonecrosis of the mandible is also called avascular necrosis of the jaw, and it is a rare complication of bisphosphonates. It is characterized with pain, swelling, exposure of bone, local infection and pathologic fractures of the jaw. With the widespread usage of bisphosphonates in bone metastasis of malignant tumors and osteoporosis, this rare complication has received more attention in recent years. Here, we reported a case of bisphosphonates-related osteonecrosis of the jaw (BRONJ) caused by intravenous zoledronic acid for osteoporosis. A 62-year-old female patient with 7-year history of Sjögren's syndrome and 3-year history of osteoporosis developed BRONJ after 3-year treatment of zoledronic acid. Two months before she went to the Peking University International Hospital, she visited the dentist for periodontal purulent secretion and extracted one tooth from the right mandible. However, the condition was not improved and she felt persistent pain and swelling in the right mandible. Hence, she received repeated root curettage, but there was no improvement. Finally, she was diagnosed with osteonecrosis of the mandible based on the digital volume tomography scan, which showed right mandibular osteonecrosis bone destruction. She underwent surgical debridement of the necrotic bone and administered intravenous antibio-tics at the Peking University International Hospital. Histopathological analysis of the bone biopsy further confirmed the diagnosis of BRONJ. Her condition was improved successfully during a 3-year follow-up. Osteonecrosis of the mandible become more common with the increased use of bisphosphonates. Recent study has reported that osteonecrosis of the mandible is more likely to occur in patients with Sjögren's syndrome. In addition, age, long-term and irregular administration of glucocorticoids, irregular oral examination and treatment also might be the risk factors in the pathogenesis of osteonecrosis of the mandible. For the elder osteoporosis patients who would receive or had received bisphosphonate-related drugs, oral health status and the disease states associated with necrosis of the mandible such as Sjögren's syndrome should be comprehensively measured and fully evaluated during the whole process. Furthermore, to better understand and prevent or reduce the occurrence of this complication, we reviewed the patho-genesis, diagnosis, treatment, and prevention of BRONJ.
Keywords: Bisphosphonate-associated osteonecrosis of the jaw; Osteoporosis; Zoledronic acid.
Conflict of interest statement
Figures
Similar articles
-
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.Osteoporos Int. 2017 Mar;28(3):1145-1147. doi: 10.1007/s00198-016-3840-z. Epub 2016 Nov 20. Osteoporos Int. 2017. PMID: 27866217
-
Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.Quintessence Int. 2016;47(5):433-40. doi: 10.3290/j.qi.a35263. Quintessence Int. 2016. PMID: 26665262
-
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.Quintessence Int. 2014 Sep;45(8):685-90. doi: 10.3290/j.qi.a32242. Quintessence Int. 2014. PMID: 25019116 Review.
-
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.Head Neck Pathol. 2007 Dec;1(2):132-40. doi: 10.1007/s12105-007-0033-2. Epub 2007 Dec 5. Head Neck Pathol. 2007. PMID: 20614264 Free PMC article. Review.
-
Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.Clin Drug Investig. 2013 Feb;33(2):117-22. doi: 10.1007/s40261-012-0041-1. Clin Drug Investig. 2013. PMID: 23184667
References
-
- Fleisch H. Biphosphonate as a therapeutic drug: Experimental studies and clinical application. Ther Umsch. 1985;42(6):366–375. - PubMed
-
- Everts-Graber J, Lehmann D, Burkard JP, et al. Risk of osteo-necrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. 2021;37(2):340–348. - PubMed
-
- 朱 洁云, 高 敏, 宋 秋韵, et al. 中国老年人骨质疏松症患病率的Meta分析. 中国全科医学. 2022;25(3):346–353.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources